Dapagliflozin Pretreatment Prevents Cardiac Electrophysiological Changes in a Diet and Streptozotocin Induction of Type 2 Diabetes in Rats: A Potential New First-Line?

References

• Maejima Y. SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function. Front Cardiovasc Med. 2020;6. doi:10.3389/fcvm.2019.00186
   PubMed Web of Science ®Google Scholar
• Ferrini M, Johansson I, Aboyans V. Heart failure and its complications in patients with diabetes: mounting evidence for a growing burden. Eur J Prev Cardiol. 2019;26(2_suppl):106–113. doi:10.1177/2047487319885461
   PubMed Web of Science ®Google Scholar
• Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17(9):585–607. doi:10.1038/s41569-020-0339-2
   PubMed Web of Science ®Google Scholar
• Borghetti G, Von Lewinski D, Eaton DM, Sourij H, Houser SR, Wallner M. Diabetic cardiomyopathy: current and future therapies. Beyond glycemic control. Front Physiol. 2018;9:1–15. doi:10.3389/fphys.2018.01514
   PubMed Web of Science ®Google Scholar
• Filardi T, Ghinassi B, Di Baldassarre A, et al. Cardiomyopathy associated with diabetes: the central role of the cardiomyocyte. Int J Mol Sci. 2019;20(13):3299. doi:10.3390/ijms20133299
   PubMed Web of Science ®Google Scholar
• Varma U, Koutsifeli P, Benson VL, Mellor KM, Delbridge LMD. Molecular mechanisms of cardiac pathology in diabetes – experimental insights. Biochim Biophys Acta Mol Basis Dis. 2018;1864(5):1949–1959. doi:10.1016/j.bbadis.2017.10.035
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Yanni J, et al. Electrical conduction system remodeling in streptozotocin-induced diabetes mellitus rat heart. Front Physiol. 2019;10:1–15. doi:10.3389/fphys.2019.00826
   PubMed Web of Science ®Google Scholar
• Stern S, Sclarowsky S. The ecg in diabetes mellitus. Circulation. 2009;120(16):1633–1636. doi:10.1161/CIRCULATIONAHA.109.897496
   PubMed Web of Science ®Google Scholar
• Konopelski P, Ufnal M. Electrocardiography in rats: a comparison to human. Physiol Res. 2016;65(5):717–725. doi:10.33549/physiolres.933270
   PubMed Web of Science ®Google Scholar
• Pabon MA, Manocha K, Cheung JW, Lo JC. Linking arrhythmias and adipocytes: insights, mechanisms, and future directions. Front Physiol. 2018;9:1–12. doi:10.3389/fphys.2018.01752
   PubMed Web of Science ®Google Scholar
• Patel KHK, Hwang T, Liebers CS, Ng FS. Epicardial adipose tissue as a mediator of cardiac arrhythmias. Am J Physiol Heart Circ Physiol. 2022;322(2):H129–H144. doi:10.1152/ajpheart.00565.2021
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Liontos A, Papakitsou I, Elisaf MS. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019;131(2):82–88. doi:10.1080/00325481.2019.1581971
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi:10.1056/NEJMoa1812389
   PubMed Web of Science ®Google Scholar
• Ni L, Yuan C, Chen G, et al. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19(1). doi:10.1186/s12933-020-01071-y
   PubMed Web of Science ®Google Scholar
• Driver C, Bamitale KDS, Kazi A, Olla M, Nyane NA, Owira PMO. Cardioprotective Effects of Metformin. J Cardiovasc Pharmacol. 2018;72(2):121–127. doi:10.1097/FJC.0000000000000599
   PubMed Web of Science ®Google Scholar
• Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31(2):119–132. doi:10.1007/s10557-017-6725-2
   PubMed Web of Science ®Google Scholar
• Nair A, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27. doi:10.4103/0976-0105.177703
   PubMedGoogle Scholar
• Argun M, Üzüm K, Sönmez MF, et al. Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats. Anatol J Cardiol. 2016;16(4):234–241. doi:10.5152/akd.2015.6185
   PubMedGoogle Scholar
• Chege BM, Waweru MP, Frederick B, Nyaga NM. The freeze-dried extracts of Rotheca myricoides (Hochst.) Steane & Mabb possess hypoglycemic, hypolipidemic and hypoinsulinemic on type 2 diabetes rat model. J Ethnopharmacol. 2019;232:244. doi:10.1016/j.jep.2019.112077
   PubMedGoogle Scholar
• Novelli ELB, Diniz YS, Galhardi CM, et al. Anthropometrical parameters and markers of obesity in rats. Lab Anim. 2007;41(1):111–119. doi:10.1258/002367707779399518
   PubMed Web of Science ®Google Scholar
• Ayala JE, Samuel VT, Morton GJ, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. DMM Dis Models Mech. 2010;3(9–10):525–534. doi:10.1242/dmm.006239
   PubMed Web of Science ®Google Scholar
• Mutiso SK, Rono DK, Bukachi F. Relationship between anthropometric measures and early electrocardiographic changes in obese rats. BMC Res Notes. 2014;7(1). doi:10.1186/1756-0500-7-931
   PubMedGoogle Scholar
• Kumar AHS. Effectively communicating the 5R’s (replace, reduce, refine, reuse, and rehabilitate) of research ethics, biomedical waste, personalized medicines and the rest. J Nat Sci Biol Med. 2012;3(1):1–2. doi:10.4103/0976-9668.95932
   PubMedGoogle Scholar
• Mauricio D, Alonso N, Gratacòs M. Chronic Diabetes Complications: the Need to Move beyond Classical Concepts. Trends Endocrinol Metab. 2020;31(4):287–295. doi:10.1016/j.tem.2020.01.007
   PubMed Web of Science ®Google Scholar
• Chen HY, Huang JY, Siao WZ, Jong GP. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol. 2020;19(1). doi:10.1186/s12933-020-01048-x
   Web of Science ®Google Scholar
• Gupta S, Gupta RK, Kulshrestha M, Chaudhary RR. Evaluation of ECG abnormalities in patients with asymptomatic type 2 diabetes mellitus. J Clin Diagn Res. 2017;11(4):OC39–OC41. doi:10.7860/JCDR/2017/24882.9740
   Google Scholar
• Ring A, Brand T, Macha S, et al. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol. 2013;12(1):70. doi:10.1186/1475-2840-12-70
   PubMedGoogle Scholar
• Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallara E. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology. 2011;22(5):660–670. doi:10.1097/EDE.0b013e318225768b
   PubMed Web of Science ®Google Scholar
• Siscovick DS, Sotoodehnia N, Rea TD, Raghunathan TE, Jouven X, Lemaitre R. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. Rev Endocr Metab Disord. 2012;11(1):53–59. doi:10.1007/s11154-010-9133-5.Type
   Web of Science ®Google Scholar
• Carlson GF, Tou CKP, Parikh S, Birmingham BK, Butler K. Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. Diabetes Therapy. 2011;2(3):123–132. doi:10.1007/s13300-011-0003-2
   PubMedGoogle Scholar
• Dhingra R, Pencina MJ, Wang TJ, et al. Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham heart study. Hypertension. 2006;47(5):861–867. doi:10.1161/01.HYP.0000217141.20163.23
   PubMed Web of Science ®Google Scholar
• Nantsupawat T, Wongcharoen W, Chattipakorn SC, Chattipakorn N. Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. Cardiovasc Diabetol. 2020;19(1):198. doi:10.1186/S12933-020-01176-4
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes. 2004;53(2):434–440. doi:10.2337/diabetes.53.2.434
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zelenkofske S, Mcmurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352(25):2581–2588.
   PubMed Web of Science ®Google Scholar
• Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):1–9. doi:10.1186/s12933-017-0658-8
   PubMedGoogle Scholar
• Yagi S, Hirata Y, Ise T, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9(1):1–7. doi:10.1186/s13098-017-0275-4
   PubMedGoogle Scholar
• Paneni F, Costantino S, Hamdani N. Regression of left ventricular hypertrophy with SGLT2 inhibitors. Eur Heart J. 2020;41(36):3433–3436. doi:10.1093/eurheartj/ehaa530
   PubMed Web of Science ®Google Scholar
• Oikonomou EK, Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol. 2019;16(2):83–99. doi:10.1038/s41569-018-0097-6
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Panagiotopoulou T, Tzavella E, Elisaf M. Clinical pharmacology of sodium glucose cotransporter 2 inhibitors. Hellenic J Atherosc. 2017;8(2):61–72.
   Google Scholar
• Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care. 2016;39(11):2036–2041. doi:10.2337/dc15-2688
   PubMed Web of Science ®Google Scholar
• Ritchie RH, Dale Abel E. Basic mechanisms of diabetic heart disease. Circ Res. 2020;126(11):1501–1525. doi:10.1161/CIRCRESAHA.120.315913
   PubMed Web of Science ®Google Scholar
• Drzewoski J, Kasznicki J, Trojanowski Z. The role of “metabolic memory” in the natural history of diabetes mellitus. Pol Arch Med Wewn. 2009;119(7–8):493–500. doi:10.20452/PAMW.747
   PubMed Web of Science ®Google Scholar
• Testa R, Bonfigli AR, Prattichizzo F, La Sala L, De Nigris V, Ceriello A. The “Metabolic Memory” theory and the early treatment of hyperglycemia in prevention of diabetic complications. Nutrients. 2017;9(5):437. doi:10.3390/nu9050437
   PubMed Web of Science ®Google Scholar
• Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–638. doi:10.1161/CIRCRESAHA.117.311586
   PubMed Web of Science ®Google Scholar